FDA Expands Afrezza Label: Inhaled Insulin Approved for Type 1 and Type 2 Diabetes in Children and Adolescents

Executive Brief

News Report

The News: FDA expands Afrezza label to include children and adolescents with diabetes.
Clinical Win: New inhaled insulin option enhances treatment for pediatric diabetes.
Target Specialty: Endocrinology

Key Data at a Glance

FDA Approval Date: 2026
Indications: Type 1 and Type 2 diabetes in children and adolescents
Administration: Inhalation via inhaler

The FDA has expanded the label for Afrezza (insulin human) inhalation powder to include children and adolescents with type 1 and type 2 diabetes, a significant development announced in early 2026. This approval is crucial for healthcare providers as it offers a new option for managing diabetes in younger populations, addressing a critical need for effective treatment options.

Clinical Context

Diabetes is a chronic condition characterized by elevated blood glucose levels due to insufficient insulin production or ineffective use of insulin by the body. The World Health Organization (WHO) reports that the prevalence of diabetes has risen dramatically, with over 800 million adults living with the condition as of 2022, and the incidence in children and adolescents is also increasing. The management of diabetes in younger patients is particularly challenging, as they often require tailored treatment strategies to ensure effective glycemic control while minimizing the risk of hypoglycemia and other complications. Inhaled insulin, such as Afrezza, provides a non-invasive alternative to traditional insulin injections, potentially improving adherence and quality of life for pediatric patients. The expanded indication for Afrezza in children and adolescents is a timely response to the growing need for innovative diabetes management solutions in this vulnerable population.

Key Findings

The FDA's approval expands the use of Afrezza to include children and adolescents with type 1 and type 2 diabetes, enhancing treatment options for this demographic.

Afrezza is designed for use in conjunction with a long-acting insulin and is indicated for the improvement of glycemic control in adults and children aged 4 years and older with diabetes.

Dosing for Afrezza is individualized based on the patient's needs, and it is administered via an inhaler, making it a convenient option for younger patients who may be hesitant about injections.

Safety & Tolerability

The approval was based on clinical data demonstrating the safety and efficacy of Afrezza in pediatric populations, with particular attention to its pharmacokinetic profile and the absence of significant respiratory adverse events in children.

What This Means for Clinical Practice

The expansion of Afrezza's indication to include children and adolescents with diabetes means that healthcare providers now have a valuable tool to manage glycemic control in younger patients. This inhaled insulin option can enhance patient adherence, particularly among those who may be resistant to traditional injection methods. Clinicians should consider incorporating Afrezza into their treatment plans for pediatric patients who require flexible and effective insulin management. Additionally, ongoing education about the proper use of inhaled insulin and monitoring for potential respiratory issues will be essential to ensure optimal patient outcomes. As the landscape of diabetes management continues to evolve, the integration of innovative therapies like Afrezza will be crucial in addressing the unique challenges faced by younger patients with diabetes.

Clinical Perspective

Workflow: Clinicians will need to adapt treatment plans to include Afrezza for younger patients.

Economics: The introduction of inhaled insulin may reduce costs associated with injection supplies.

Patient Outcomes: Improved adherence to insulin therapy is expected to enhance glycemic control in pediatric patients.

Dr. Amit Desai, Endocrinology

FDA Expands Afrezza Label: Inhaled Insulin Approved for Type 1 and Type 2 Diabetes in Children and Adolescents

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

Safety & Tolerability

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Endocrinology in your inbox.

Related Drug Updates

Semaglutide: Key Differences Between Ozempic and Wegovy for Diabetes and Weight Loss

FDA Approves Orforglipron for Chronic Weight Management in Adults with Obesity

FDA Approves Insulin Icodec for Type 2 Diabetes: First Once-Weekly Insulin

Verified HCP Portal